Published in Eur Heart J Acute Cardiovasc Care on June 01, 2012
A decade of changes in clinical characteristics and management of elderly patients with non-ST elevation myocardial infarction admitted in Italian cardiac care units. Open Heart (2014) 0.80
Contemporary Trends and Age-Specific Sex Differences in Management and Outcome for Patients With ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc (2016) 0.79
Clinical disease registries in acute myocardial infarction. World J Cardiol (2014) 0.75
Knowledge translation lessons from an audit of Aboriginal Australians with acute coronary syndrome presenting to a regional hospital. SAGE Open Med (2016) 0.75
Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review. Curr Cardiol Rev (2017) 0.75
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (2003) 19.90
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Reassessment of clinical practice guidelines: go gently into that good night. JAMA (2009) 5.91
Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78
Care in U.S. hospitals--the Hospital Quality Alliance program. N Engl J Med (2005) 5.74
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J (2002) 3.56
Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation (2006) 3.08
Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation (2004) 2.90
Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction. Eur Heart J (2010) 2.01
Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol (2006) 1.94
Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J (2003) 1.76
ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol (2008) 1.60
Indicators of quality of care for patients with acute myocardial infarction. CMAJ (2008) 1.46
Epidemiology and patterns of care of patients admitted to Italian Intensive Cardiac Care units: the BLITZ-3 registry. J Cardiovasc Med (Hagerstown) (2010) 1.43
Medication performance measures and mortality following acute coronary syndromes. Am J Med (2005) 0.99
Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J (2005) 0.99
The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. Arch Intern Med (2009) 0.97
Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative). Am J Cardiol (2006) 0.91
Guideline implementation research: exploring the gap between evidence and practice in the CRUSADE Quality Improvement Initiative. Acad Emerg Med (2007) 0.90
ACCF/AHA new insights into the methodology of performance measurement: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures. Circulation (2010) 0.89
Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. Can J Cardiol (2009) 0.82
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34
[Distribution and appropriateness of hospital admissions, resource utilization in the Italian intensive cardiac care units. The BLITZ-3 study]. G Ital Cardiol (Rome) (2011) 2.34
Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2004) 2.31
Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J (2002) 2.27
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 2.09
Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. Int J Cardiol (2013) 2.04
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation (2010) 2.00
Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation (2012) 1.99
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. Int J Cardiol (2013) 1.95
Time from adenosine di-phosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome: meta-analysis and meta-regression. Int J Cardiol (2013) 1.94
[Prognostic significance of the elevation of the indices of myocardial damage after percutaneous coronary revascularization interventions]. Ital Heart J Suppl (2002) 1.90
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC Cardiovasc Interv (2012) 1.83
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J (2012) 1.82
Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J (2005) 1.80
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail (2010) 1.78
Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J (2003) 1.76
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail (2008) 1.65
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J (2009) 1.63
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. JACC Cardiovasc Interv (2008) 1.63
Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram. Circ Heart Fail (2012) 1.59
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail (2004) 1.57
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J (2013) 1.56
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. Eur J Heart Fail (2010) 1.55
Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation (2013) 1.55
Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study. JACC Cardiovasc Interv (2010) 1.54
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol (2006) 1.54
Participation versus education: the GISSI story and beyond. Am Heart J (2004) 1.52
Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol (2008) 1.49
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Eur Heart J (2009) 1.48
Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens (2012) 1.47
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J (2009) 1.47
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart (2013) 1.45
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J (2003) 1.44
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens (2007) 1.43
Early invasive versus selectively invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: impact of age. Catheter Cardiovasc Interv (2014) 1.43
Epidemiology and patterns of care of patients admitted to Italian Intensive Cardiac Care units: the BLITZ-3 registry. J Cardiovasc Med (Hagerstown) (2010) 1.43
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum? J Hypertens (2012) 1.41
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention (2014) 1.41
[Determinants of late-onset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results]. Rev Esp Cardiol (2005) 1.41
[Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation]. G Ital Cardiol (Rome) (2012) 1.40
[Heart failure: the importance of a disease management program]. G Ital Cardiol (Rome) (2007) 1.40
Implementation of beta-blockade in elderly heart failure patients: role of the nurse specialist. Eur J Cardiovasc Nurs (2007) 1.39
Half-dose thrombolysis to begin with, when immediate coronary angioplasty in acute myocardial infarction is not possible. Ital Heart J (2004) 1.39
[The evolution of medical research: from trials to tailored therapy]. G Ital Cardiol (Rome) (2010) 1.39
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation (2011) 1.35
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 1.34
Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med (2008) 1.32
Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol (2005) 1.31
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J (2013) 1.30
Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J (2006) 1.30